Form 4: Adaptive Biotechnologies Director Acquires Shares

Adaptive Biotechnologies Director Peter M. Neupert acquired 15,625 shares of common stock at a $0 price.

Summary

• Peter M. Neupert, a Director of Adaptive Biotechnologies Corp (ADPT), acquired 15,625 shares of the company's common stock.
• The transaction occurred on March 4, 2026, with an acquisition price of $0 per share.
• Following this acquisition, Mr. Neupert directly beneficially owns a total of 240,315 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's a routine compensation grant, it increases the director's direct ownership, aligning their interests with shareholders.

Positives

• A director's acquisition of shares, even at a $0 price (typically a grant), aligns their interests further with shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly acquisitions, are routinely monitored by investors as they can signal management's confidence in the company's future prospects. While this specific transaction is a grant, it is a standard component of executive and director compensation in the biotechnology sector, aiming to align leadership incentives with long-term shareholder value.

Comparison to Industry Standards

• Director stock grants at a $0 exercise price are a common form of equity compensation across the biotechnology and broader technology industries, similar to practices at companies like Illumina or Guardant Health, where directors receive restricted stock units or options as part of their compensation packages to foster long-term alignment.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholder value through greater equity ownership.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine insider stock acquisition (likely a grant) and does not provide new fundamental information that would alter an investment thesis. It reinforces director alignment but does not warrant a change in investment recommendation based solely on this disclosure.

Keywords

Adaptive Biotechnologies, ADPT, Insider Transaction, Form 4, Director Stock Acquisition, Common Stock, Peter M. Neupert